Novartis confirms closure of Horsham R&D facility

Novartis (NVS) has confirmed fears that it will shut its R&D facility in Horsham in southern England by the end of June.

The plant employs 400 staffers and 170 consultants.

The closure is part of Novartis' global reorganization as it concentrates more of its R&D around three major hubs: Basel, Boston and Shanghai.

There could be more to come, as CEO Joe Jimenez recently told analysts that there was room to cut the company's $7B budget.

From other sites
Comments (1)
  • Tom Foster
    , contributor
    Comment (1) | Send Message
    Employees told by email sent on behalf of the senior management team who were hiding in their offices in Basel as none of them had the guts to go to Horsham and makes the announcement face to face.
    26 Feb 2014, 10:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs